Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

How patient insights were brought to life with graphic novel outputs

How patient insights were brought to life with graphic novel outputs

Our client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks. Their new product promised greater freedom from these acute attacks and therefore from the associated burden. The challenge was to understand why many patients remain on older therapy types and how the pathway to more modern therapy options, with better efficacy and side effect profiles, could be mapped out for physicians and patients. Our client further requested that insights from the research were brought to life in the insights workshop meeting in a new and impactful way.
 

read more »

  • Posted by Dr. Chris Gaj
  • June 25, 2019
  • Articles

The Promise and Pitfalls of Molecular Testing in Oncology

 The Promise and Pitfalls of Molecular Testing in Oncology

Dr. Chris Gaj explores the challenges and potential consequences for stakeholders in the US, Europe and emerging markets in the latest issue of pharmaphorum's Deep Dive (Published June 2019).

Early targeted therapies, such as the tyrosine kinase inhibitor erlotinib from Roche/Genentech/OSI, offered the promise of precision medicine to treat cancer at a molecular level. Oncologists noted individual “Lazarus-like” responses to erlotinib, but overall effectiveness was moderate in unselected populations. It was not until the discovery that specific activating mutations in the epidermal growth factor receptor (EGFr) conveyed sensitivity to erlotinib that oncologists could identify the patients most likely to respond and target them for treatment while limiting exposure to those unlikely to respond.

read more »

  • Posted by Mariel Metcalfe
  • June 25, 2019
  • News

Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports

Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports

Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients in France, Germany, Italy, Spain and UK, while the AS US report is based on a study of 136 patients.  The Living with nr-AxSpA report comprises of interviews with a total of 78 patients in the 5EU and the US. All of the studies consist of 30-minute quantitative online interviews and for the AS studies 30 minute qualitative tele-depth interviews. The reports are available to purchase in the following formats: AS (5EU), AS (US) and nr-AxSpA (5EU & US).

read more »

  • Posted by Rachel Howard & Brett Gardiner
  • June 20, 2019
  • Events

ISPOR Annual Conference 2019

ISPOR Annual Conference 2019

Last month, Directors Brett Gardiner and Rachel Howard attended the ISPOR annual conference in New Orleans.

With over 4,000 delegates in attendance and a three-day program packed with panel presentations, poster sessions, educational symposia and workshops, this is the leading global conference for health economics and outcomes research.

read more »

  • Posted by Pei Li Teh
  • June 11, 2019
  • Articles

Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?

Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?

China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets

It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics. 

read more »